A Phase 2 interventional study of Dupilumab in Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD) and Eosinophilic Gastrointestinal Disease (EGID), sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 53 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Eosinophilic enteropathy with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Eosinophilic enteropathy · United States.
Among the 26 studies in Eosinophilic enteropathy with a site in United States, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 2, and was the 26th registered.
28 studies on the registry are indexed under Eosinophilic enteropathy; 5 are open to participants now.
Browse Eosinophilic enteropathy studies →4 of the 26 studies in Eosinophilic enteropathy with a site in United States are open now. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 18–59
Ann & Robert H Lurie Children's Hospital of Chicago · Sites in United States
Ages 1–25
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 3+
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Eosinophilic enteropathy studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 6 · Phase 4 1
First in 1996; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 36 across 16 interventional studies indexed under Eosinophilic enteropathy.
Median enrollment 28 across the 16 interventional studies, 335 across the 10 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 26 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 1 study filed under Eosinophilic enteropathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Eosinophilic enteropathy with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage.
The aim of the study is to evaluate the effect of dupilumab on relieving EoG (with or without EoD) symptoms and reducing inflammation in the stomach and, if applicable, small intestine in adults and adolescents aged 12 years and older after at least 24 weeks (about 6 months) and up to 52 weeks (1 year) of treatment.
The study is looking at several other research questions, including:
This study has 2 parts and a 12-week (about 3 months) Follow-up Period for all participants
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Treatment Period Part C: Extended Treatment Period Eligible participants from Part A will enter Part C
Drug: Dupilumab
Administered as described in the protocol
Also known as: DUPIXENT®, REGN668, SAR231893
Percent change in peak gastric eosinophil count eosinophils/high power field (eos/hpf)
Time frame: Baseline up to 24 Weeks
Percent change in peak gastric eosinophil count eosinophils/high power field (eos/hpf)
Time frame: Baseline up to 52 Weeks
Proportion of participants achieving a peak gastric eosinophil count of ≤20 eos/hpf
Time frame: Up to 52 Weeks
Proportion of participants achieving a peak gastric eosinophil count of ≤30 eos/hpf
Time frame: Up to 52 Weeks
Proportion of participants achieving both a peak gastric eosinophil count of ≤20 eos/hpf and a peak duodenal eosinophil count of ≤30 eos/hpf
Time frame: Up to 52 Weeks
Proportion of participants achieving a peak duodenal eosinophil count of ≤30 eos/hpf
Assessed for only those with duodenal involvement
Time frame: Up to 52 Weeks
Absolute change in the EoG/EoD-SQ Total Symptom Score (TSS)
EoG/EoD-SQ is a PRO collected daily via an eDiary. Symptoms are assessed using an 11-point numerical rating scale (0 through 10). Higher scores indicate a higher symptom burden. Symptom scores are summed on each day with a maximum daily score of 60. The TSS is calculated by averaging daily sum scores over 7 days, with a maximum TSS of 60.
Time frame: Baseline up to 52 Weeks
Percent change in the EoG/EoD-SQ TSS
Time frame: Baseline up to 52 Weeks
Percent change in peak duodenal tissue eosinophil count (eos/hpf)
Assessed for only those with duodenal involvement
Time frame: Baseline up to 52 Weeks
Absolute change in EoG scores from the EoG Histology Scoring System (EoGHSS)
EoGHSS scores evaluate 11 features of gastric tissue. Total score is the sum of features scores divided by the maximum possible score for the biopsy. Total scores range from 0 - 1.
Time frame: Baseline up to 52 Weeks
Change in frequency of diarrhea episodes
Assessed for only those with diarrhea at baseline
Time frame: Baseline up to 52 Weeks
Change in frequency of vomiting episodes
Assessed for only those with vomiting at baseline
Time frame: Baseline up to 52 Weeks
Change in the Normalized Enrichment Scores (NES) for the type 2 inflammation transcriptome signature
Assessed on gastric tissue Normalized Enrichment Score (NES) reflects the degree to which the activity level of a set of transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set.
Time frame: Baseline up to 52 Weeks
Change in the NES for the type 2 inflammation transcriptome signature
Assessed on duodenal tissue from participants with EoD NES reflects the degree to which the activity level of a set of transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set.
Time frame: Baseline up to 52 Weeks
Change in the NES for the EoG disease (EoG diagnostic panel (EGDP]) transcriptome signature
Assessed on gastric tissue NES reflects the degree to which the activity level of a set of transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set.
Time frame: Baseline up to 52 Weeks
Proportion of participants who receive rescue medications or procedures
Time frame: Up to 52 Weeks
Incidence of treatment-emergent adverse events (TEAEs)
A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Time frame: Up to 52 Weeks
Incidence of treatment-emergent serious adverse events (SAEs)
An SAE is any untoward medical occurrence that at any dose: * Results in death - includes all deaths, even those that appear to be completely unrelated to study drug (eg, a car accident in which a patient is a passenger) * Is life-threatening * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event
Time frame: Up to 52 Weeks
Incidence of treatment-emergent adverse events of special interest (AESIs)
An AESI (serious or non-serious) is one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the sponsor can be appropriate. Such an event might warrant further investigation in order to characterize and understand it
Time frame: Up to 52 Weeks
Incidence of TEAEs leading to permanent discontinuation of study treatment
A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Time frame: Up to 52 Weeks
Incidence of anti-drug antibody (ADA)
Immunogenicity will be characterized per drug molecule by ADA status
Time frame: Up to 52 Weeks
Titer of ADA
Immunogenicity will be characterized per drug molecule by ADA status
Time frame: Up to 52 Weeks
Incidence of neutralizing antibody (NAb) to dupilumab
Immunogenicity will be characterized per drug molecule by NAb status
Time frame: Up to 52 Weeks
Concentrations of functional dupilumab in serum at each assessment time point
The concentrations of functional dupilumab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.
Time frame: Baseline up to 64 Weeks
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from May 2023 to primary completion in Feb 2026, 33 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab